PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsfocal segmental glomerulosclerosis
MeSH D005923 - focal segmental glomerulosclerosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D005921:Glomerulonephritis
$
Success rate
D005923: 
Focal segmental glomerulosclerosis
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaCyclosporine Cyclosporine  2005-03-25   
PadagisCyclosporine Cyclosporine  2003-10-07   
MylanCyclosporine Cyclosporine  2022-02-02   
SandozCyclosporine Cyclosporine  2000-01-13   
AbbVieCyclosporine Cyclosporine  2000-03-03   
Cyclosporine Gengraf  2000-05-12   
Cyclosporine Restasis Multidose 2024-08-27 2002-12-23   
NovartisCyclosporine Neoral  1995-07-14 $379 M Q2/19-Q2/22 
Cyclosporine Sandimmune  1983-11-14   
Sun Pharmaceutical IndustriesCyclosporine Cequa 2033-08-23 2018-08-14   
ApotexCyclosporine Cyclosporine  2002-05-09   
Strides Pharma GlobalCyclosporine Cyclosporine  2022-08-02   
Hikma PharmaceuticalsCyclosporine Cyclosporine  1999-10-29   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
50%
2/4
Phase 2
33%
9/27
Phase 3
22%
4/18
Approved: 2Overall Success rate: 4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
AbbVie
Novartis
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use